A chronic lung infection with Pseudomonas aeruginosa is associated with an increased exacerbation and mortality rate in people affected by bronchiectasis. Inhaled antibiotics are frequently used in clinical practice to treat chronic infections with this bacterium. The PROMIS-I and PROMIS-II studies investigated the efficacy and safety of 12-month inhaled colistimethate sodium administration in patients with bronchiectasis and chronic P. aeruginosa infection.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Rare pulmonary syndromes
Yellow nail and Swyer-James syndrome
- Internal thoracoscopy
Diagnostic indications
- Follow-up care for head and neck cancer
What is the significance of FDG PET-CT?
- Important basics and studies on cancer and the psyche
Interplay between cancer and mental illness
- Systemic lupus erythematosus
Increased risk of pulmonary manifestations
- Postmenopausal osteoporosis: long-term therapy concepts
Targeted use of antiresorptives and osteoanabolic agents and avoid “rebound” effects
- Late-onset rheumatoid arthritis
More DMARDs can reduce glucocorticoids in LORA
- Atopic dermatitis